ART812是一种口服有效的DNA聚合酶θ（Polθ）小分子抑制剂，其IC50值为7.6nM。
Cas No.:2607138-82-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ART812 is an orally bioavailable small-molecule inhibitor of DNA polymerase theta (Polθ) with an IC50 value of 7.6nM[1]. ART812 acts through an allosteric mechanism of inhibition, targeting the polymerase domain of Polθ, thereby eliciting synthetic lethality in tumor cells deficient in homologous recombination (HR) repair[2]. ART812 has demonstrated single-agent anti-tumor efficacy in preclinical studies against models of PARP inhibitor-resistant cancer[3-4].
In vitro, ART812 (100-500nM) treatment of HEK293 cells transfected with a microhomology-mediated end joining (MMEJ) reporter for 24 hours significantly inhibits TMEJ-mediated DNA repair activity[5].
In vivo, ART812 (100mg/kg) administered orally once daily (QD) to female SRG OncoRats bearing established MDA-MB-436 BRCA1 mutant, SHLD2 knockout tumor xenografts significantly inhibited tumor growth and was well-tolerated over a 76-day treatment period[1].
References:
[1] Zatreanu D, Robinson HMR, Alkhatib O, et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun. 2021 Jun 17;12(1):3636.
[2] Barszczewska-Pietraszek G, Drzewiecka M, Czarny P, et al. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours. Int J Mol Sci. 2022 Dec 24;24(1):319.
[3] Bazan Russo TD, Mujacic C, Di Giovanni E, et al. Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors. Cancer Gene Ther. 2024 Nov;31(11):1619-1631.
[4] Federica G, Michela C, Giovanna D. Targeting the DNA damage response in cancer. MedComm (2020). 2024 Oct 31;5(11):e788.
[5] Stockley ML, Ferdinand A, Benedetti G, et al. Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta. J Med Chem. 2022 Oct 27;65(20):13879-13891.
ART812是一种口服有效的DNA聚合酶θ（Polθ）小分子抑制剂，其IC50值为7.6nM[1]。ART812通过变构抑制方式作用于Polθ的聚合酶结构域，从而在同源重组修复（HR）缺陷的肿瘤细胞中引发合成致死效应[2]。ART812在临床前研究中显示出对PARP抑制剂耐药肿瘤模型的单药抗癌功效[3-4]。
在体外，ART812（100-500nM）处理转染microhomology-mediated end joining（MMEJ）的HEK293细胞24小时，可显著抑制MMEJ介导的DNA修复活性[5]。
在体内，ART812（100mg/kg）每日一次口服给药，用于处理携带MDA-MB-436 BRCA1突变且SHLD2敲除肿瘤的雌性Rats。ART812显著抑制了肿瘤生长，并在76天的治疗期间表现出良好的耐受性[1]。
| Cell experiment [1]: | |
Cell lines | HEK293 cells (human embryonic kidney cell line) |
Preparation Method | HEK293 cells were transfected with a NanoLuciferase-encoding TMEJ (Theta-Mediated End Joining) reporter substrate and a Firefly luciferase plasmid (for normalization). Cells were treated with ART812 (100–500nM) for 24 hours. |
Reaction Conditions | 100–500nM; 24 hours |
Applications | ART812 significantly inhibited TMEJ-mediated DNA repair in HEK293 cells, demonstrating a cellular EC50 of 150nM. |
| Animal experiment [2]: | |
Animal models | Female athymic nude mice (immunodeficient model) |
Preparation Method | Mice were treated with either vehicle control or ART812 (150mg/kg; oral administration) for 4 days. Whole blood was collected on day 5 and fixed using a Mouse MicroFlow kit. Blood samples were analyzed for micronucleated reticulocytes (MN-RETs) by flow cytometry. |
Dosage form | 150mg/kg; oral administration |
Applications | ART812 treatment demonstrated a 2-fold induction of micronuclei in reticulocytes, as measured by flow cytometry, indicating significant DNA damage and target engagement of Polθ. |
References: | |
| Cas No. | 2607138-82-7 | SDF | Download SDF |
| 分子式 | C19H16ClF4N3O4 | 分子量 | 461.79 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1655 mL | 10.8274 mL | 21.6549 mL |
| 5 mM | 433.1 μL | 2.1655 mL | 4.331 mL |
| 10 mM | 216.5 μL | 1.0827 mL | 2.1655 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet